Ecorobotix Secures $150M to Accelerate AI-Powered Plant-by-Plant™ Care, Unveiling New Innovation at Agritechnica

ECBF

Yverdon-les-Bains, Switzerland – 13 October 2025 – Ecorobotix, the global leader in AI-powered Ultra-High Precision (UHP) spraying, is driving the future of sustainable agriculture with innovations that improve crop health and efficiency. Building on rapid growth, proven field results, and a strong financial foundation with $150 million raised in Series C ($45m, 2024) and Series D ($105m, 2025), the company will present its latest advancements at Agritechnica this November in Hanover.

Central to Ecorobotix’s momentum is its Plant-by-Plant™ AI technology, which can distinguish and treat each individual plant with unmatched precision, using a spray footprint of just a few centimeters. This approach reduces the use of pesticides and other crop protection products by as much as 95% while maintaining effectiveness. For growers, the benefits are far-reaching: the safe use of non-selective products, lower input costs, compliance with increasingly strict regulations, and ultimately, higher yields.

Fueling Innovation Through Investment
These new advances are made possible thanks to the company’s strong backing from global investors. The Series D round was led by Highland Europe, one of the continent’s top venture capital funds, with ECBF and McWin Capital Partners also joining as new investors.

 “These latest investment rounds have allowed us to accelerate our innovation, expand into new crop types, broaden our product range, and bring our advanced crop algorithms to market faster,” said Dominique Mégret, CEO of Ecorobotix. “Thanks to the trust of our investors, we are scaling a proven solution to help deliver better-quality food for the world.”

Showcasing New Innovation at Agritechnica 2025
This November at Agritechnica, Ecorobotix will unveil its latest innovation, setting a new standard for crop protection worldwide.
“Farmers today face rising costs, labor shortages, and pressure to reduce inputs while still producing more food,” added Mégret. “Our new innovation takes precision even further to help them meet those challenges.” 

About our New Investors

Highland Europe
Highland Europe invests in exceptional growth-stage technology and consumer companies. Formally launched in 2012, Highland Europe has raised over €2.75 billion. Highland’s collective history of investments across the US, Europe and China includes 45+ IPOs, 150+ M&A exits and 40 billion-dollar-plus companies.

ECBF
The European Circular Bioeconomy Fund (ECBF) is the leading venture capital fund dedicated to accelerating Europe’s transition to a sustainable, circular bioeconomy. With €300 million under management, ECBF invests in growth-stage companies. As an Article 9 SFDR fund, ECBF combines rigorous ESG standards with deep industry expertise to scale impactful innovations.

McWin Capital Partners
McWin Capital Partners (“McWin”) is a specialist private equity and venture capital firm, dedicated to the food ecosystem. With deep industry expertise across three business segments; Food Tech, Foodservice and Restaurants, McWin’s purpose is to lead the food industry through positive change and create value on behalf of investors and portfolio companies of the McWin Funds by leveraging its scale, network and experience to deliver outstanding returns.

Ecorobotix also acknowledges the vital support of its long-term partners such as 4FOX Ventures, AQTON, BASF Venture Capital, Capagro, Cibus Capital, Flexstone Partners, Fondation Domaine de Villette, Meritech, Stellar Impact, Swisscanto, Swisscom Ventures, and Yara Growth Ventures.

About Ecorobotix
Ecorobotix is a Swiss B Corporation® certified company whose mission is to transform agriculture through artificial intelligence and ultra-precise spraying technologies. With more than 25 crop algorithms now supported, its flagship product, ARA, is the world’s most versatile ultra-high-precision sprayer, capable of targeting specific crops as well as different types of weeds. Present in more than 20 countries in Europe, the Americas, and Oceania, Ecorobotix is redefining the standards of sustainable crop protection.

Press contact | ECBF Management GmbH
Cornelia Mann | pr@ecbf.vc| +49.160.892.774.4

Our Investment in n8n: The AI platform for automation

Accel

Enterprises have reached a tipping point in their AI investments. Pilots are widespread, but most companies have yet to translate those experiments into full workflow transformations. Their ability to capture the value that AI promises depends on integrating an increasing number of task and function-specific AI agents and systems across their businesses.

n8n has built the missing piece that enterprises need in order to translate their AI investments into real, durable value for their organizations. Its central system of record enables companies to build, evaluate, observe, and orchestrate agentic automations across their global operations, all while integrating directly into their existing workflows through over 1,000 native integrations, APIs, ETL connectors, and MCPs.

Accel’s Ben Fletcher and n8n’s Jan Oberhauser together in Berlin.

Today, we’re pleased to announce that Accel has led the Series C in n8n’s AI-native workflow automation platform. This funding round follows explosive, capital-efficient growth over the past year that has seen n8n become the underlying infrastructure for orchestrating and integrating agents into leading enterprises. We’re grateful to be joined by a variety of angels and strategic partners, including CrowdStrike’s George Kurtz, NVIDIA’s NVentures, and Deutsche Telekom’s T.Capital.

Previous generations of automation software relied on “if this, then that” deterministic logic. It’s a fundamental mismatch for agentic AI workflows, and diminishes the potential value LLMs promise. n8n has built the automation and orchestration layer for the AI era: today, more than 80% of workflows built on n8n embed AI agents.

n8n has dramatically expanded the share of work that can be automated. Teams can fully customize workflows, mixing AI agents with deterministic steps and team inputs where required. The range of use cases on n8n is vast: AI builders define full backend logic. Fortune 500 companies standardize operations spanning IT, finance, marketing automation, and security orchestration. System integrators have transformed customer support, sales, and DevOps with easy AI automations. No matter where customers are on their AI journey, n8n makes it easy to unlock real value and efficiency gains.

What truly sets n8n apart is its radically open “Fair Code” model and the community it has inspired. n8n has become a Top 50 GitHub Project with over 145,000 stars, and is now supported by a vibrant community of more than 700,000 active developers. n8n users also tend to be n8n evangelists: extending it through workflow templates and integrations, and spreading the word across online forums. Community members now organize over 60 community events around the world each year.  In this, we’ve recognized a similarity with some of Accel’s most notable investments – Atlassian, Slack, Vercel, Webflow –  that built effusive, loyal communities centered around great products.

n8n events around the world focused on builders

At Accel, we’ve long believed in partnering with the builders creating the foundational tools powering software. Accel portfolio companies Cursor, Linear, Lovable, Supabase and Vercel are rapidly defining the next-gen AI stack. n8n is the next step of this thesis, providing the open, community-first operating system to embed AI into daily work. We’re grateful to Jan and his team for trusting Accel as a partner for their next phase of global growth and we look forward to the remarkable journey ahead.

France-based Phagos lands $29m to further develop its antibiotic alternative for livestock

Agfund

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Phagos.]

Paris, France-based biotech company Phagos has raised a €25 million ($29 million) Series A round to further develop its bacteriophage drugs used to treat bacterial disease in animals and, eventually, humans.

The company calls these drugs “a sustainable answer to the global challenge of bacterial resistance.” It will use the funding to deploy treatments, starting with animal health, as well as further develop its technology that simplifies the discovery process.

CapAgroHoxton VenturesCapHorn, and Demeter co-led the round, which also saw participation from Acurio VenturesCitizen CapitalEntrepreneur FirstFounders Capital, and Station F.

Drug pipeline to fight AMR ‘insufficient’ 

Phagos’ fundraise news comes just days after the World Health Organization released new reports that detail the escalating problem of antimicrobial resistance (AMR) and the “insufficient” pipeline of drugs and innovations needed to tackle drug-resistant bacterial infections.

AMR is expected to cause some 39 million deaths globally over the next 25 years. It is also a leading cause of death among animals, which raises food security and livelihood concerns in addition to those around animal welfare.

In its new reports, the WHO calls for “greater investment in tools designed for resource-limited settings, including those that eliminate the need for culture and simplifying diagnostic platforms for primary and secondary care use.”

The promise of phage therapy 

Bacteriophage—or simply “phages”—are present in everything from soil to the human gut, and regulate the number of bacteria in humans, plants, and animals.

Phagos says that thanks to millions of years of co-evolution with bacteria, phages are specialized to detect specific bacterial targets without harming other cells. This makes them an attractive potential alternative to antibiotics. In animal health, for example, they could be used to treat salmonella or E. coli.

The Phagos platform, dubbed “Alphagos,” combines microbiology with artificial intelligence to diagnose bacterial strains, identify phages that can fight those strains, and develop “ultra-targeted bacterial treatments” that leverage phages, says the company.

These treatments are continuously updated to ensure subjects stay healthy without contributing to AMR.

The company, founded in 2021, has started with solutions for animal health, which it says can be tailored to the needs of a specific livestock operation or environment. Currently, the Phagos phage therapy is deployed across the chicken, cattle, swine, and shrimp sectors. Phagos also recently filed a patent for its AI platform.

“We are convinced that phage therapy can transform the history of medicine just as antibiotics did in the last century,” noted Phagos’ founders Alexandros Pantalis and Adèle James.

“Thanks to our regulatory breakthroughs and our patented platform combining microbiology and artificial intelligence, we now have the opportunity to establish phage therapy as a global reference solution: for animal health today, and for human health tomorrow.”

The Series A financing will go towards further deployment of veterinary phage therapy in the field. Funds will also enable further development of the Alphagos platform as well as international expansion across Europe, Asia, and the Americas.

Paris, France-based biotech company Phagos has raised a €25 million ($29 million) Series A round to further develop its bacteriophage drugs used to treat bacterial disease in animals and, eventually, humans.

The company calls these drugs “a sustainable answer to the global challenge of bacterial resistance.” It will use the funding to deploy treatments, starting with animal health, as well as further develop its technology that simplifies the discovery process.

CapAgroHoxton VenturesCapHorn, and Demeter co-led the round, which also saw participation from Acurio VenturesCitizen CapitalEntrepreneur FirstFounders Capital, and Station F.

Drug pipeline to fight AMR ‘insufficient’ 

Phagos’ fundraise news comes just days after the World Health Organization released new reports that detail the escalating problem of antimicrobial resistance (AMR) and the “insufficient” pipeline of drugs and innovations needed to tackle drug-resistant bacterial infections.

AMR is expected to cause some 39 million deaths globally over the next 25 years. It is also a leading cause of death among animals, which raises food security and livelihood concerns in addition to those around animal welfare.

In its new reports, the WHO calls for “greater investment in tools designed for resource-limited settings, including those that eliminate the need for culture and simplifying diagnostic platforms for primary and secondary care use.”

The promise of phage therapy 

Bacteriophage—or simply “phages”—are present in everything from soil to the human gut, and regulate the number of bacteria in humans, plants, and animals.

Phagos says that thanks to millions of years of co-evolution with bacteria, phages are specialized to detect specific bacterial targets without harming other cells. This makes them an attractive potential alternative to antibiotics. In animal health, for example, they could be used to treat salmonella or E. coli.

The Phagos platform, dubbed “Alphagos,” combines microbiology with artificial intelligence to diagnose bacterial strains, identify phages that can fight those strains, and develop “ultra-targeted bacterial treatments” that leverage phages, says the company.

These treatments are continuously updated to ensure subjects stay healthy without contributing to AMR.

The company, founded in 2021, has started with solutions for animal health, which it says can be tailored to the needs of a specific livestock operation or environment. Currently, the Phagos phage therapy is deployed across the chicken, cattle, swine, and shrimp sectors. Phagos also recently filed a patent for its AI platform.

“We are convinced that phage therapy can transform the history of medicine just as antibiotics did in the last century,” noted Phagos’ founders Alexandros Pantalis and Adèle James.

“Thanks to our regulatory breakthroughs and our patented platform combining microbiology and artificial intelligence, we now have the opportunity to establish phage therapy as a global reference solution: for animal health today, and for human health tomorrow.”

The Series A financing will go towards further deployment of veterinary phage therapy in the field. Funds will also enable further development of the Alphagos platform as well as international expansion across Europe, Asia, and the Americas.

ValueFactory VC – Another successful exit and dividend distribution

Value Factory

At Value Factory, we build companies together with entrepreneurs that create both impact and value. Today, we’re proud to share that we’re once again delivering a solid return to our investors.

This result is the outcome of:

  • a successful exit from an early-stage investment that no longer fits within our current sustainability focus,
  • and the first returns from our bio-based investments.

Our approach proves itself: we combine entrepreneurship with strategic, hands-on support and a sharp focus on growth sectors where innovation and sustainability go hand in hand. In doing so, we continuously seek synergy between our portfolio companies.

Biobased & Agritech: the perfect match

We strongly believe in the power of Agritech and biobased construction. Agritech innovations help farmers and horticulturists produce more efficiently and sustainably, creating new, high-quality streams of natural raw materials. These find their way into the construction sector, where demand for biobased materials (such as wood, hemp, or mycelium) is growing exponentially.

This creates a circular chain: agriculture provides the raw materials, technology makes them efficiently available, and the construction sector uses them to reduce the massive CO₂ emissions of buildings. This is precisely where the strength – and the future – of Value Factory lies.

We are grateful for the trust of our investors and proud of the entrepreneurs with whom we make this happen. And this is just the beginning: we are further stepping up our focus on sustainable and biobased innovations for the built environment – solutions that contribute to a livable future while delivering attractive returns.

Final opportunity to get in

Our current investment round is approaching its close. For those who still want to join, now is the moment.

Categories: News

Tags:

AtaCor Medical Secures $75M Financing to Support the Pivotal U.S. Study of its Extravascular ICD (EV-ICD) System

Arboretum

The novel design of AtaCor’s Atala™ lead aims to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies with no hardware placed in the heart or vasculature

SAN CLEMENTE, Calif.Oct. 6, 2025 /PRNewswire/ — AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems, announced today that it has entered into a financing of up to $75 million. The proceeds will fund the company’s U.S. FDA Pivotal Study evaluating AtaCor’s parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system for the treatment of life-threatening ventricular tachyarrhythmias.

“There is a clear and growing need for extravascular ICD systems that combine a straightforward implant procedure with the ability to deliver the full spectrum of tachyarrhythmia therapies using a small pulse generator,” said Rick Sanghera, Chief Executive Officer of AtaCor Medical. “AtaCor is poised to meet that need. We are proud to close this financing round and excited to initiate our pivotal trial next year.”

 

AtaCor’s EV-ICD system consists of the Atala™ lead and an implantable pulse generator. The Atala™ lead is implanted via a small left parasternal incision, positioned through the rib space with electrodes placed against the pericardium, outside of the heart and vasculature.  The pulse generator can be placed in either a lateral or pectoral subcutaneous device pocket, representing a novel option for EV-ICD systems. This unique EV-ICD system aims to deliver the benefits of defibrillation and antitachycardia pacing without the long-term risks associated with intravascular or intracardiac leads.

“The AtaCor team is developing a meaningful solution for patients, while protecting the integrity of the heart for future interventions,” commented Maria Berkman, Chair of the AtaCor Board of Directors.  “The Board is delighted to see this infusion of capital in support of AtaCor’s pivotal trial, bringing this important technology one step closer to the bedside.”

AtaCor recently completed enrollment of its ASCEND EV Pilot Study, with initial results accepted for presentation at the upcoming Asia Pacific Heart Rhythm Society (APHRS) meeting this November in Yokohama, Japan. Building on these initial results, AtaCor plans to launch the ALARION EV Pivotal Study in the United States and Europe in 2026, which aims to evaluate the safety and efficacy of the parasternal EV-ICD system and support global regulatory submissions.

The AtaCor EV-ICD Lead System is under development exclusively for investigational use and is not approved for sale in any geography.

About AtaCor Medical, Inc.

AtaCor Medical is transforming cardiac pacing and defibrillation with its proprietary extravascular ICD (EV-ICD) system. The novel design provides the full range of therapeutic capabilities of traditional implantable defibrillators, including defibrillation and antitachycardia pacing, without placing hardware inside the heart or vascular system. AtaCor’s technology both preserves future cardiac treatment options and overcomes key limitations of existing ICD systems.

AtaCor venture investors include Arboretum Ventures, Broadview Ventures, Longview Ventures, Hatteras Venture Partners, Catalyst Health Ventures, and BayMed Venture Partners.

For more information, please visit www.atacor.com.

SOURCE AtaCor Medical Inc.

Categories: News

Tags:

Telmai + Atlan unify trust and context to scale autonomous enterprise AI systems

.406 Venture

AI pilots fail not because models don’t work, but because data systems lack reliability and context. To scale AI responsibly, enterprises need validated data at the source and metadata enriched with health and governance signals. This article shows how Telmai and Atlan close this gap. Telmai validates data as it lands, while Atlan’s Metadata Lakehouse adds lineage and governance to create the trusted foundation for scaling AI.

Telmai + Atlan

 

Anoop Gopalam October 3, 2025

With a surge in AI investment, enterprise leaders are under mounting pressure to deliver reliable, scalable AI solutions that create measurable business impact. A recent MIT study found that 95  percent of generative AI projects failed to produce measurable outcomes, as many organizations struggle to move beyond experimentation and into reliable execution. AI pilots are failing to deliver, not because the models don’t work, but because the underlying foundational data systems upon which they are built lack reliability and context.

Autonomous systems and AI agents act on data in microseconds, so there’s no time for late-stage downstream fixes where most companies focus their data quality efforts today. To power AI-native ecosystems at scale, organizations must build trust at the source as data is ingested and ensure that data quality metadata is pushed to data catalogs and metadata systems, allowing agents to evaluate fitness before consumption. This creates the trusted foundation that Autonomous AI products need to operate reliably and at scale.

image
Image source – The AI Value Chasm

By combining Telmai’s AI-first data quality platform with Atlan’s AI-native metadata and governance platform through Atlan’s App Framework, enterprises gain a seamless way to detect, resolve, and govern data issues directly within the tools their teams already use.

In this article, let’s dive deeper into how they together create a single fabric of trust + context that allows enterprises to move beyond pilots and scale AI responsibly.

Why is real-time validation at ingestion critical for reliable AI?

The failure point for most AI initiatives isn’t in the model, but rather it’s in the underlying data pipeline feeding it. Business Intelligence (BI) is inherently deterministic and descriptive, working with structured historical data to explain what happened through predefined reports and dashboards. AI, in contrast, is non-deterministic and predictive. It consumes both structured and unstructured data to learn patterns, forecast outcomes, and make autonomous decisions.

The old adage “garbage in, garbage out” takes on far higher stakes here. AI and LLMs always identify patterns from the inputs they receive and derive insights without context or judgment. If those inputs are incomplete, drifting, or biased, the model confidently reproduces those flaws at scale.
Traditional data quality approaches were designed for a reporting world, where errors could be corrected after a dashboard broke or a KPI looked suspicious. AI-native workloads break this model entirely. AI and autonomous systems operate at machine speed, where thousands of micro-decisions are made every second. Waiting until the BI or monitoring layer to enforce quality is simply too late, as the damage has already propagated through to downstream business-critical applications.

That’s why ingestion-layer validation has become non-negotiable. Data quality must be ensured before Agentic workflows can access or read the data, not after the data lands in the access layer, at the data lake, or before it enters the lake through event streams. Reliability must be enforced as data is ingested into the lake, especially in open formats like Apache Iceberg and Delta Lake, where it is profiled and validated before being published to production tables.

image

This is exactly where Telmai comes in. Purpose-built for AI-first architectures, Telmai continuously monitors and validates data through your data pipeline, irrespective of volume or velocity. Telmai’s ML-driven and rule-based checks automatically detect anomalies, schema changes, and data drift before they impact production. Further, Telmai can publish data health KPIs into data catalogs and metadata systems like Atlan, enriching lineage and governance with real-time data quality context.

Agentic AI systems don’t have the luxury of waiting for late-stage fixes. They act in microseconds. That means trust must be built into data at ingestion, and that trust must travel with context across the enterprise, “ said Mona Rakibe, Co-Founder and CEO of Telmai. “With the App Framework, Telmai and Atlan will give teams a trusted data layer ready to power applications and integrations that let AI move beyond pilots and deliver at scale.”

How Atlan extends this trust with context

Trust in data is only half the story. For enterprises to scale AI responsibly, trust must travel with context so every consumer, whether human, system, or AI agent, knows what the data means, where it came from, and how it can be used.

As part of Atlan’s new App Framework, Telmai is now integrated directly into Atlan’s Metadata Lakehouse. For the first time, enterprises can unify monitoring within the same foundation that powers column-level lineage, business-ready data products, AI governance, and policy & compliance monitoring.

With this integration, customers using Telmai and Atlan can:

  • Unify trust and context in the Metadata Lakehouse – Telmai’s data quality signals, such as freshness, anomaly detection, schema changes, and volume drift, are automatically surfaced inside Atlan, enhancing lineage and metadata with actionable insights that empower data consumers and AI agents alike.
  • Enable true interoperability for agentic AI – For agentic systems to truly scale, interoperability is critical. The tools and services that agents depend on,  whether for validation, access, enrichment, or downstream action, must be accessible through a common layer. Atlan delivers this through its open Metadata Lakehouse by providing consistent, versioned context across raw ingestion data and curated data products, ensuring data fitness can be evaluated at every step.
  • Enforce policy and compliance at scale – With Telmai’s data quality metadata embedded in the context layer, data trust signals can flow downstream via column-level lineage and bidirectional tag management to other platforms like Databricks, Snowflake, or data access systems. When Data Quality issues are encountered, they can trigger automated governance workflows, ensuring policy compliance and reducing risk across autonomous AI pipelines.

Enterprises can’t scale AI responsibly without a foundation of trust and context. Telmai brings real-time, ingestion-level validation, and Atlan serves as the context layer, ensuring that trust travels with context across every system, workflow, and AI agent.” said Marc Seifer, Head of Global Alliances at Atlan. “Together, Telmai and Atlan are enabling organizations to move beyond pilots and build AI systems that operate reliably, responsibly, and at scale.”

Get AI-Ready—Now

For enterprises to successfully transition AI pilots into production, they need real-time, low-latency access to validated data, along with metadata that carries context about its health, lineage, and governance. Without this foundation, AI agents operate blindly, lacking visibility into whether the data they consume is fit for use, where it originated, or whether they are authorized to access it.

Telmai and Atlan close this gap. Telmai continuously monitors and validates data in open table formats, such as Apache Iceberg and more, as it lands in the lake layer, detecting anomalies and data quality issues before they propagate downstream. It then generates rich observability metadata, which flows into Atlan’s Metadata Lakehouse. There, these signals are combined with lineage, policies, and business glossaries, providing a complete picture of data health and context for both humans and AI agents.

By bringing Telmai’s data quality signals into Atlan’s Metadata Lakehouse, enterprises can now drive measurable impact on their AI implementation with reliability and context fabric that enables AI to scale responsibly.
Want to learn how Telmai and Atlan can work together to scale your existing data infrastructure to be AI-ready? Click here to connect with our team for a personalized demo.

Want to stay ahead on best practices and product insights? Click here to subscribe to our newsletter for expert guidance on building reliable, AI-ready data pipelines.

Onapsis Partners with Microsoft to Boost Enterprise Defense with End-to-End SAP Security Monitoring

.406 Venture

Onapsis Defend integration with Microsoft Sentinel Solution for SAP helps Security Operations teams strengthen SAP threat detection and response

 

BOSTON, MA., September 30, 2025 – Onapsis, a global leader in SAP cybersecurity and compliance, today announced the launch of a new integration between its flagship Onapsis Defend threat monitoring product and Microsoft Sentinel Solution for SAP, based on Microsoft’s AI-powered cloud-native Security Information and Event Management (SIEM) platform. The integration provides security operations centers (SOC) with unified visibility and threat detection and response capabilities for SAP security events.

SOC teams struggle with a profound visibility gap into activity happening in their mission-critical SAP landscapes, which commonly serve as foundational systems of record for enterprises. This gap includes identifying SAP threats, detecting SAP-targeted exploits and zero-day activity, suspicious user or insider behavior, sensitive data downloads, security control violations and more. The new integration provides organizations with a superior early warning system with proprietary exploit detection rules for business-critical SAP applications, enabling their security teams to detect exploit attacks on vulnerable SAP systems before patches are even released.

“The collaboration extends the power of Onapsis’ SAP-endorsed, industry-leading threat monitoring directly into Microsoft Sentinel Solution for SAP,” said Sadik Al-Abdulla, Onapsis Chief Product Officer. “By unifying Onapsis’ context-rich insights with Microsoft Sentinel’s Solution for SAP, enterprises can investigate and respond to SAP threats faster, meet strict disclosure requirements with confidence and strengthen their security posture across both on-prem, cloud and RISE with SAP environments.”

Key benefits of the integration include:

  • Specialized Exploit and Zero-Day Detection: The Microsoft Sentinel Solution for SAP offers advanced pre-patch exploit protection and early warning alerts against cyberattacks, enriched with threat intelligence from Onapsis Research Labs and their Global SAP Threat Intelligence Network. This collaboration enhances Microsoft Sentinel’s native SAP capabilities with specialized insights from one of the industry’s most trusted research teams.
  • Context-Rich Alerts, Designed for the SOC: SAP events are uniquely enriched with detailed explanations, mitigation guidance, and anomaly scoring from the SAP cybersecurity experts at the Onapsis Research Labs to accelerate investigations
  • AI-Powered Security Insights: The powerful Microsoft Sentinel Solution for SAP and Microsoft Security Copilot AI capabilities, combined with the security insights and threat intelligence from Onapsis, offer superior identification of sophisticated attacks affecting your SAP and broader environment.
  • Unified Security Operations: With market-leading SAP threat and exploit detection from Onapsis, organizations can push security events to Microsoft Sentinel Solution for SAP for correlation with broader enterprise events to streamline incident handling and reduce response times through a unified view of the overall threat landscape in the Microsoft Unified SecOps Platform.

“Microsoft takes a holistic approach to SAP security, moving beyond isolated conversations. By integrating threat intelligence across the enterprise, and Security Copilot into Microsoft Defender Portal, we demonstrate that security isn’t limited to SAP Applications or data – it is about the whole ecosystem,” said Martin Pankraz, Product Manager, SAP Security, Microsoft. “Onapsis complements that effort with their market-leading pre-breach capabilities such as SAP exploit and zero-day detection, SAP Vulnerability Management or ABAP Code Security. We’re delivering deeper protection for our customers’ SAP landscapes, empowering them to respond to SAP threats faster and keeping them far ahead of the latest SAP attacks and exploitation techniques from malicious threat actors.”

It has been a watershed year for defenders marked by a series of high-profile SAP vulnerabilities, zero-days and global attack campaigns that led to hundreds of enterprises being compromised. Despite SAP’s rapid patching, security practitioners are still faced with the ongoing challenge of protecting their business-critical applications in a sophisticated threat landscape. Considering the notable success of well-funded threat actor groups targeting SAP applications, directly combined with significantly stricter regulatory requirements under EU NIS2 and SEC rules in the US, and the looming deadline for migration to SAP S/4HANA through RISE with SAP, organizations find themselves under unprecedented pressure to better secure their SAP landscapes. The Onapsis integration with Microsoft Sentinel Solution for SAP directly addresses these challenges by giving SOC teams the visibility and control needed to rapidly respond to an increasing number of threats to critical SAP systems.

Availability

The Onapsis Defend for Microsoft Sentinel Solution for SAP integration is available today. Pricing and further details available through Onapsis sales representatives or authorized systems integrators. For more information, please visit the Microsoft Azure Marketplace.

About Onapsis

Onapsis is the global leader in SAP cybersecurity and compliance, trusted by the world’s leading organizations to securely accelerate their SAP cloud digital transformations with confidence. As the SAP-endorsed and most widely used solution to protect SAP, the Onapsis Platform empowers Cybersecurity and SAP teams with automated compliance, vulnerability management, threat detection, and secure development for their RISE with SAP, S/4HANA Cloud and hybrid SAP applications. Powered by threat insights from the Onapsis Research Labs, the world’s leading SAP cybersecurity experts, Onapsis provides unparalleled protection, ease of use, and rapid time to value, empowering SAP customers to innovate faster and securely. Connect with Onapsis on LinkedInX, or visit https://www.onapsis.com.

Categories: News

Tags:

BeSound: Diagnosing Masses for the Masses

Kindred Ventures

Our Investment in BeSound

Breast cancer screening is broken. Mammograms, invented in the 1950s, remain the dominant tool despite their limitations. They miss 40% of breast cancers in women with dense breast tissue. The process itself is slow and fragmented: book a doctor’s appointment, wait weeks, undergo a manual exam, then a screening image, then a diagnostic image. For many women, this means weeks of anxiety while answers remain out of reach. The FDA recently updated its guidelines requiring providers to notify women with dense breasts that mammograms may not be enough, sending 40 million women a letter that underscores the shortcomings of today’s system.

BeSound is building an alternative: AI-powered ultrasound that collapses weeks of steps into a single visit. By pairing FDA-approved photo-acoustic ultrasound machines with proprietary AI, BeSound delivers precise functional imaging tailored to each woman’s biology. Unlike mammograms, BeSound delivers answers in hours and has been shown in real-world studies to reduce unnecessary biopsies by up to 75%.

That vision is why we’re excited be co-leading BeSound’s $6.76 million seed alongside Overwater Ventures, Muse Capital, and Lux Capital.

Why We Invested

After an hour with Bailey Renger, we were immediately struck by her unusual background. Her technical expertise, knack for brand, and intuition for the changing shape of healthcare present a rare triple threat. Bailey began her career in science, working in an optics lab, at NASA, and at Harvard in quantum computing before starting a PhD in physics at Brown. But during that time, she faced a medical crisis: “I always wanted to be a physics professor… but when I started experiencing severe pain, my doctors told me it was just cramps. I pushed for an ultrasound, and they found a tumor in my ovary. Then I had to wait months for an MRI. That gap in care was the catalyst for me leaving my PhD to start this company.”

Her story underscores why she is so close to the problem. With one in eight women expected to face breast cancer, Bailey’s blend of scientific training and lived urgency gives BeSound a rare edge. The company is positioned to deliver fast, accurate, and scalable diagnostics—offering hope to millions.

Looking Ahead

BeSound is launching first in Los Angeles with its inaugural West Hollywood location, where women can book same day appointments starting at $349. The company is expanding rapidly, including New York in the coming months, bringing FDA approved technology, hospital grade precision, and expert reviewed results within 24 hours.

In the near future, breast cancer screening will shift from decades-old, one size fits all mammograms to AI-powered functional imaging that adapts to each woman’s biology. The future isn’t just about finding cancers earlier, it’s about giving women fast, precise answers, and building an experience that puts them at the center of care.

Join the waitlist at BeSound.

Categories: News

Tags:

Credo Acquires Hyperlume to Advance the Future of AI Connectivity

SOSV

Today, we’re excited to announce that our SOSV portfolio company and HAX startup development program graduate Hyperlume, a pioneer in MicroLED-based optical interconnect technology, has been acquired by Credo (NASDAQ: CRDO).

This marks a major step forward in delivering secure, high-speed connectivity solutions that are more reliable, energy efficient, and ready for the AI era.

Impact on the AI World

The explosion of AI and hyperscale data center workloads is pushing existing connectivity infrastructure to its limits. Traditional electronic interconnects face serious energy and bandwidth bottlenecks that slow scaling and increase costs.

GPU performance has improved ~40,000x since 2000. But the networks that connect those chips have only improved ~80x, creating a significant bottleneck. Today, most GPUs still transfer data via copper cables, an antiquated method that’s cheap but highly inefficient (it generates excessive heat and wastes energy). Laser-based optical cables exist, but they’re 5x more expensive than copper and don’t scale well within tightly packed racks where 40% of the interconnects live.

To keep pace with the exponential growth of data, the world needs a new class of connectivity.

That’s where Hyperlume’s breakthrough MicroLED technology comes in. By using high bandwidth, low latency, low power interconnects for AI data centers and high-performance computing systems, Hyperlume has created a new way to overcome the energy and bandwidth bottlenecks inherent in traditional electronic interconnects.

With this acquisition, Credo now offers one of the most comprehensive connectivity platforms in the industry and strengthens their ability to help customers scale massive AI networks more efficiently and sustainably.

Huge congratulations to Hyperlume co-founders Mohsen Asad (CEO) and Hossein Fariborzi (CTO). When they first joined HAX in 2023, as part of our ever-expanding thesis into next-gen compute and data centres power, their mix of deep technical expertise and conviction is why we invested early.

Read more in Credo’s press release announcing the acquisition here.

Emerald backs FREDsense in $7M Series A to speed up PFAS field testing

Emerald

Calgary, Canada — Emerald has announced its participation in FREDsense’s USD $7 million Series A funding round, led by HG Ventures. FREDsense delivers practical, next-generation solutions for detecting PFAS —“forever chemicals”— by providing fast, portable testing equipment that allows customers to get results in hours rather than weeks.

The company has launched the first commercially available field-based PFAS detector and has seen early adoption across industries such as environmental consulting & services, water and wastewater treatment, energy and general industrial operations. By replacing lengthy lab turnaround times with same-day answers onsite, FREDsense enables onsite teams to identify contamination hotspots, verify cleanups, and optimize treatment more efficiently and at lower cost.

“FREDsense is bringing much-needed speed and practicality to PFAS testing,” said Clayton MacDougald, Investment Director at Emerald and newly appointed FREDsense Board Member. “When you can get reliable results the same day, you make better decisions, finish jobs faster, and reduce costs. We’re thrilled to back this team alongside HG Ventures.”

“Communities and companies need cleaner water, faster answers, and fewer delays,” said Ginger Rothrock, Senior Director at HG Ventures. “FREDsense puts lab-level insight into the hands of field teams, which is exactly what this moment requires. We’re proud to lead the round and support FREDsense as they scale.”

“Our mission is simple: make PFAS testing fast, accessible, and actionable,” said David Lloyd, CEO of FREDsense. “With support from HG Ventures and Emerald, we’ll expand production, deepen customer support, and continue improving our product so more sites can get answers on the spot.”

Looking ahead

FREDsense is building toward long-term relevance in a market of extreme importance, where PFAS sits at the intersection of environmental urgency, human health concerns, regulatory enforcement and economic opportunity within a  global multi-billion-dollar problem. With its first-mover advantage, growing commercial traction, and scalable business model, FREDsense represents a compelling opportunity for players in the PFAS space that are seeking differentiated tools to strengthen their portfolios and respond to regulatory and customer demand.

Categories: News

Tags: